Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA.
Intensive Care Med. 2015 Sep;41(9):1549-60. doi: 10.1007/s00134-015-3822-1. Epub 2015 May 8.
To determine whether early goal-directed therapy (EGDT) reduces mortality compared with other resuscitation strategies for patients presenting to the emergency department (ED) with septic shock.
Using a search strategy of PubMed, EmBase and CENTRAL, we selected all relevant randomised clinical trials published from January 2000 to January 2015. We translated non-English papers and contacted authors as necessary. Our primary analysis generated a pooled odds ratio (OR) from a fixed-effect model. Sensitivity analyses explored the effect of including non-ED studies, adjusting for study quality, and conducting a random-effects model. Secondary outcomes included organ support and hospital and ICU length of stay.
From 2395 initially eligible abstracts, five randomised clinical trials (n = 4735 patients) met all criteria and generally scored high for quality except for lack of blinding. There was no effect on the primary mortality outcome (EGDT: 23.2% [495/2134] versus control: 22.4% [582/2601]; pooled OR 1.01 [95% CI 0.88-1.16], P = 0.9, with heterogeneity [I(2) = 57%; P = 0.055]). The pooled estimate of 90-day mortality from the three recent multicentre studies (n = 4063) also showed no difference [pooled OR 0.99 (95% CI 0.86-1.15), P = 0.93] with no heterogeneity (I(2) = 0.0%; P = 0.97). EGDT increased vasopressor use (OR 1.25 [95% CI 1.10-1.41]; P < 0.001) and ICU admission [OR 2.19 (95% CI 1.82-2.65); P < 0.001]. Including six non-ED randomised trials increased heterogeneity (I(2) = 71%; P < 0.001) but did not change overall results [pooled OR 0.94 (95% CI 0.82 to 1.07); P = 0.33].
EGDT is not superior to usual care for ED patients with septic shock but is associated with increased utilisation of ICU resources.
确定与其他复苏策略相比,早期目标导向治疗(EGDT)是否能降低因败血症休克而到急诊就诊的患者的死亡率。
我们采用了 PubMed、Embase 和 CENTRAL 的搜索策略,筛选了 2000 年 1 月至 2015 年 1 月发表的所有相关随机临床试验。我们翻译了非英文论文,并在必要时联系了作者。我们的主要分析通过固定效应模型生成了合并优势比(OR)。敏感性分析探讨了纳入非急诊研究、调整研究质量以及进行随机效应模型的影响。次要结局包括器官支持和医院及 ICU 住院时间。
从 2395 篇最初合格的摘要中,有 5 项随机临床试验(n = 4735 名患者)符合所有标准,除了缺乏盲法外,总体质量评分较高。初级死亡率结局无影响(EGDT:23.2%[495/2134]与对照组:22.4%[582/2601];合并 OR 1.01[95%CI 0.88-1.16],P = 0.9,异质性[I(2) = 57%;P = 0.055])。来自三项最近的多中心研究(n = 4063)的 90 天死亡率的合并估计也显示无差异[合并 OR 0.99(95%CI 0.86-1.15),P = 0.93],无异质性(I(2) = 0.0%;P = 0.97])。EGDT 增加了血管加压素的使用(OR 1.25[95%CI 1.10-1.41];P < 0.001)和 ICU 入院率[OR 2.19(95%CI 1.82-2.65);P < 0.001]。纳入 6 项非急诊随机试验增加了异质性(I(2) = 71%;P < 0.001),但总体结果无变化[合并 OR 0.94(95%CI 0.82-1.07);P = 0.33]。
EGDT 并不优于常规护理治疗因败血症休克而到急诊就诊的患者,但与 ICU 资源的使用增加有关。